[ Price : $8.95]
FDA approves a Scholar Rock BLA for Isembyld (apitegromab-mstn) injection to treat spinal muscular atrophy.[ Price : $8.95]
FDA seeks input on whether traditional statistical standards should be modified for rare disease clinical investigations, includin...[ Price : $8.95]
FDAs approval of Outlook Therapeutics Lytenava shows that the agencys willingness to accept one adequate and well-controlled trial...[ Price : $8.95]
AstraZeneca and Daiichi Sankyo says that Enhertu cut the risk of disease progression or death by 37% compared with pembrolizumab (...[ Price : $8.95]
AstraZeneca says that its Etcamah (camizestrant) failed to significantly improve progression-free survival in the Phase 3 SERENA-4...[ Price : $8.95]
Saint Louis University law professor Michael S. Sinha says FDAs next commissioner should focus on rebuilding the agencys depleted ...[ Price : $8.95]
A new report from the Association for Accessible Medicines calls for changes to FDA policies, patent law, pharmacy benefit manager...[ Price : $8.95]
FDA grants Pharming Group expanded approval for Joenja (leniolisib) tablets for treating activated phosphoinositide 3-kinase delta...